Citadel Advisors LLC Takes $617,000 Position in Neos Therapeutics Inc (NEOS)

Citadel Advisors LLC acquired a new stake in shares of Neos Therapeutics Inc (NASDAQ:NEOS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 67,442 shares of the company’s stock, valued at approximately $617,000. Citadel Advisors LLC owned about 0.25% of Neos Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NEOS. JPMorgan Chase & Co. purchased a new stake in Neos Therapeutics during the third quarter valued at approximately $120,000. Cortina Asset Management LLC purchased a new stake in Neos Therapeutics during the third quarter valued at approximately $5,312,000. Bank of New York Mellon Corp increased its holdings in Neos Therapeutics by 37.7% during the third quarter. Bank of New York Mellon Corp now owns 81,617 shares of the company’s stock valued at $747,000 after buying an additional 22,363 shares during the last quarter. New York State Common Retirement Fund increased its holdings in Neos Therapeutics by 67.3% during the third quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock valued at $159,000 after buying an additional 7,000 shares during the last quarter. Finally, Essex Investment Management Co. LLC increased its holdings in Neos Therapeutics by 24.2% during the third quarter. Essex Investment Management Co. LLC now owns 238,152 shares of the company’s stock valued at $2,179,000 after buying an additional 46,423 shares during the last quarter. 45.93% of the stock is owned by hedge funds and other institutional investors.

Neos Therapeutics Inc (NASDAQ:NEOS) opened at $9.90 on Monday. Neos Therapeutics Inc has a 12-month low of $4.85 and a 12-month high of $13.15. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.14 and a current ratio of 2.42.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.22. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. The firm had revenue of $6.70 million during the quarter. research analysts expect that Neos Therapeutics Inc will post -2.87 EPS for the current fiscal year.

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Cowen reiterated a “buy” rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. Finally, Wells Fargo & Company set a $14.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. Neos Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.00.

ILLEGAL ACTIVITY WARNING: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/12/11/citadel-advisors-llc-takes-617000-position-in-neos-therapeutics-inc-neos.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics Inc (NASDAQ:NEOS).

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply